Explore the frontier of ALK+ NSCLC treatments in this in-depth session from the 2022 Targeted Therapies Forum, led by the esteemed Dr. Millie Das. As ALK+ NSCLC continues to be a central topic in oncological research, this video sheds light on the most promising emerging therapies and their potential implications for patient care.
Special thanks to our dedicated sponsors: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech, for their continued support in pushing the boundaries of cancer treatment and research.
Stay updated with the latest breakthroughs in cancer treatment and research. Dive deeper at http://cancerGRACE.org/. Engage with a community of experts and peers at https://cancergrace.org/forum.